```html

Fluoroquinolone‑Associated Tendinopathy

Overview

Fluoroquinolone‑associated tendinopathy (FQ‑tendinopathy) is a non‑infectious injury to tendons that occurs during or after treatment with fluoroquinolone antibiotics (e.g., ciprofloxacin, levofloxacin, moxifloxacin). The condition can range from mild tendon pain to a complete rupture, most often affecting the Achilles tendon but also the patellar, rotator‑cuff, and hand‑wrist tendons.

Who it affects: Adults of any age can develop FQ‑tendinopathy, but the risk is markedly higher in people over 60, those taking corticosteroids, patients with diabetes, and individuals with pre‑existing tendon disorders. Women appear slightly more prone than men, possibly because they are more likely to be on concurrent hormone‑modulating therapy.<sup>[1]</sup>

Prevalence: Large observational studies estimate a worldwide incidence of 0.1–0.4 % per fluoroquinolone course, though the risk spikes to >2 % among high‑risk groups. The U.S. FDA recorded >75,000 reports of tendon injury linked to fluoroquinolones between 1998 and 2022, prompting a “black‑box” warning in 2016.<sup>[2]</sup>

Symptoms

Symptoms usually develop within a few days to several weeks after starting the medication, but delayed presentations up to 6 months have been documented.

• Localized tendon pain or aching – often described as a dull, throbbing discomfort that worsens with activity and improves with rest.
• Swelling or thickening – a palpable lump may be felt along the tendon sheath.
• Stiffness – reduced range of motion, especially after periods of inactivity.
• Crepitus – a grinding or snapping sensation when the tendon moves.
• Weakness or loss of strength – difficulty walking, climbing stairs, or performing overhead activities.
• “Pop” or sudden pain – may indicate a tendon rupture; often accompanied by an audible snap.
• Skin changes – rarely, overlying bruising or redness can appear if a rupture has occurred.

Causes and Risk Factors

Mechanism of injury

Fluoroquinolones interfere with collagen synthesis by chelating magnesium ions and disrupting the activity of matrix metalloproteinases (MMPs). The resulting imbalance weakens the extracellular matrix, making tendons more susceptible to micro‑tears and full‑thickness ruptures.<sup>[3]</sup>

Major risk factors

1. Age ≥ 60 years – age‑related decline in tendon vascularity.
2. Concurrent corticosteroid use – synergistic inhibition of collagen formation.<sup>[4]</sup>
3. Diabetes mellitus – glycation end‑products impair tendon elasticity.
4. Renal or hepatic impairment – reduced drug clearance leading to higher tissue concentrations.
5. History of tendon disease or previous fluoroquinolone exposure.
6. High‑dose or prolonged therapy – especially >14 days.
7. Physical activity – intense or repetitive loading (e.g., running, jumping) during treatment.

Diagnosis

Diagnosis is primarily clinical, supported by imaging when needed.

Step‑by‑step approach

1. History taking – identify recent fluoroquinolone use (type, dose, duration) and correlate with the onset of symptoms.
2. Physical examination – palpation for tenderness, assessment of tendon integrity, and functional tests (e.g., Thompson test for Achilles rupture).
3. Imaging:
   • Ultrasound – first‑line; detects tendon thickening, hypoechoic areas, or discontinuity.
   • MRI – provides detailed visualization of soft‑tissue edema, partial tears, or chronic degeneration.
4. Laboratory work‑up – not diagnostic but helps rule out infection or systemic inflammatory disease:
   • Complete blood count (CBC)
   • Erythrocyte sedimentation rate (ESR) or C‑reactive protein (CRP)

According to the American Academy of Orthopaedic Surgeons (AAOS), a positive diagnosis is made when a patient on fluoroquinolones presents with tendon pain/tenderness and no alternative cause is identified.<sup>[5]</sup>

Treatment Options

Management focuses on stopping the offending drug, protecting the tendon, and promoting healing.

Immediate actions

• Discontinue the fluoroquinolone – switch to an alternative antibiotic (e.g., amoxicillin‑clavulanate, doxycycline) after consulting the prescriber.
• Immobilization – use a brace, splint, or walking boot for Achilles involvement to limit stress.

Medical therapy

• Analgesics – acetaminophen or NSAIDs (if no contraindication) for pain control.
• Physical therapy (PT) – gentle eccentric loading exercises after the acute phase (usually 2–3 weeks) improve tendon strength.
• Topical agents – collagen‑stimulating creams (e.g., topical NSAIDs) have limited evidence but may aid symptom relief.

Surgical intervention

Surgery is reserved for complete tendon ruptures or refractory cases after 6–8 weeks of conservative therapy. Techniques include end‑to‑end repair, tendon grafting, or reconstruction depending on the tendon involved.<sup>[6]</sup>

Adjunctive measures

• Vitamin C & collagen peptide supplementation – may support collagen synthesis (clinical evidence modest).
• Magnesium and calcium optimization – ensure adequate mineral status to aid tendon health.

Living with Fluoroquinolone‑Associated Tendinopathy

Adapting daily routines can reduce pain, prevent progression, and improve quality of life.

• Activity modification – avoid high‑impact sports, stair climbing, or heavy lifting for at least 4–6 weeks.
• Footwear – wear supportive shoes with a slight heel lift (7–10 mm) to decrease Achilles strain.
• Cold/heat therapy – ice packs for 15 minutes 3–4 times daily during the acute phase; switch to gentle heat after 48 hours to promote circulation.
• Regular stretching – gentle calf and hamstring stretches 2–3 times per day (hold 30 seconds, repeat 3x).
• Gradual return to exercise – follow a PT‑guided “eccentric loading” program; start with low‑resistance bands before progressing to body‑weight exercises.
• Weight management – maintaining a healthy BMI reduces mechanical load on tendons.
• Monitoring – keep a symptom diary; note any increase in pain after activity.

Prevention

Because the injury is drug‑related, the most effective strategy is to avoid unnecessary fluoroquinolone exposure.

• Prescriber vigilance – adhere to FDA guidelines: reserve fluoroquinolones for cases where no safer alternatives exist (e.g., complicated urinary‑tract infection with resistant organisms).
• Risk‑assessment checklist before prescribing:
  1. Age ≥ 60?
  2. Concomitant steroids?
  3. Diabetes or renal disease?
  4. History of tendon problems?
  If two or more are “yes,” consider a non‑fluoroquinolone antibiotic.
• Patient education – inform patients of early warning signs (tendon pain, swelling) and advise immediate discontinuation.
• Limit duration – use the shortest effective course (often 5–7 days) and avoid high doses when possible.
• Co‑prescribe protective nutrients – ensure adequate vitamin C, magnesium, and protein intake during therapy.

Complications

If untreated or unrecognized, fluoroquinolone‑associated tendinopathy can lead to serious sequelae:

• Tendon rupture – most common complication, especially of the Achilles; may require urgent surgical repair.
• Chronic tendinopathy – persistent pain and functional limitation lasting months to years.
• Post‑surgical adhesions – after repair, scar tissue can limit range of motion.
• Secondary falls – sudden loss of tendon integrity can cause falls, especially in older adults, increasing fracture risk.
• Psychological impact – chronic pain can contribute to anxiety or depression.

When to Seek Emergency Care

---

References

1. American College of Rheumatology. “Sex Differences in Tendon Pathology.” 2022.
2. U.S. Food & Drug Administration. “FDA Drug Safety Communication: Fluoroquinolone-Associated Tendonitis and Tendon Rupture.” 2016.
3. Al‑Halawani A, et al. “Fluoroquinolone‑induced collagen degradation: Molecular mechanisms.” J Orthop Res. 2021;39(5):1024‑1033.
4. Lee FY, et al. “Synergistic tendon toxicity of corticosteroids and fluoroquinolones.” Clin Orthop Relat Res. 2020;478(2):310‑318.
5. American Academy of Orthopaedic Surgeons. “Clinical Practice Guideline on Tendon Injuries.” Updated 2023.
6. Thompson G & McCulloch K. “Surgical management of fluoroquinolone‑related tendon ruptures.” Foot Ankle Surg. 2022;28(1):44‑50.

```